# NADIM II (NCT03838159)

> NADIM II: Neo-Adjuvant Immunotherapy

No report yet. It can be ordered.

- Drugs tested: nivolumab
- Indication: resectable stage III non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03838159
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Fundación GECP
- Conditions: Non Small Cell Lung Cancer
- Interventions: Paclitaxel; Carboplatin; Nivolumab
- Enrollment: 90
- Primary outcome: Evaluation of the pathological complete response (pCR)

## Indexed commentary on NADIM II so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 2
- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nadim-ii-nct03838159